- Home
- NAVI vs DNTH Comparison
NAVI vs DNTH Comparison
Compare NAVI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- DNTH
- Stock Information
- Founded
- NAVI 1973
- DNTH 2015
- Country
- NAVI United States
- DNTH United States
- Employees
- NAVI N/A
- DNTH N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NAVI Finance
- DNTH Health Care
- Exchange
- NAVI Nasdaq
- DNTH Nasdaq
- Market Cap
- NAVI 1.3B
- DNTH 1.5B
- IPO Year
- NAVI N/A
- DNTH N/A
- Fundamental
- Price
- NAVI $13.11
- DNTH $38.88
- Analyst Decision
- NAVI Hold
- DNTH Strong Buy
- Analyst Count
- NAVI 8
- DNTH 10
- Target Price
- NAVI $14.19
- DNTH $66.38
- AVG Volume (30 Days)
- NAVI 761.8K
- DNTH 989.4K
- Earning Date
- NAVI 10-29-2025
- DNTH 11-06-2025
- Dividend Yield
- NAVI 4.84%
- DNTH N/A
- EPS Growth
- NAVI N/A
- DNTH N/A
- EPS
- NAVI 0.31
- DNTH N/A
- Revenue
- NAVI $584,000,000.00
- DNTH $4,854,000.00
- Revenue This Year
- NAVI N/A
- DNTH N/A
- Revenue Next Year
- NAVI N/A
- DNTH N/A
- P/E Ratio
- NAVI $42.80
- DNTH N/A
- Revenue Growth
- NAVI N/A
- DNTH 17.87
- 52 Week Low
- NAVI $10.53
- DNTH $13.37
- 52 Week High
- NAVI $16.44
- DNTH $39.70
- Technical
- Relative Strength Index (RSI)
- NAVI 45.50
- DNTH 84.91
- Support Level
- NAVI $12.78
- DNTH $36.00
- Resistance Level
- NAVI $13.25
- DNTH $24.81
- Average True Range (ATR)
- NAVI 0.37
- DNTH 2.76
- MACD
- NAVI -0.05
- DNTH 1.05
- Stochastic Oscillator
- NAVI 30.28
- DNTH 95.37
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.